LOS ANGELES, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Limitless X Holdings, Inc. (OTCQX: LIMX). Dear Valued Shareholders, On behalf of the Board of Directors and Management Team at Limitless X Holdings, Inc., I am pleased to share an important update on the Significant Progress we have made in Repositioning and Strengthening our Company over the past several months. This Letter is both a Reflection on where we have been and a Vision for where we are heading.Limitless X: A Transformed Company, Built for Phenom ...

当健康与长寿成为全球共识，来自挪威的高端营养品牌NYO3以磷虾油为核心的健康解决方案，正逐步 走进更多中国家庭。近日，NYO3在上海绿地全球商品贸易港挪威集合馆开出中国大陆首店，这不仅是 一家零售空间的亮相，更是"挪威品质"与中国市场深度融合的新起点。 NYO3诞生于"长寿之国"挪威，那里因纯净自然和健康基因享誉全球。品牌自创立以来，始终坚持以磷 虾油为核心，打造全系列营养补充方案。NYO3的核心原料均采自南极威德尔海48区无污染海域，依托 挪威严格的可持续捕捞标准，从源头保证纯净天然，所有产品均在挪威本土拥有30余年历史的Nutrition Lab工厂生产，该工厂以制药级标准管理流程，生产过程全透明、全可追溯，确保每一粒磷虾油胶囊都 凝聚着挪威对健康的严谨态度。 凭借这份对品质的执着，NYO3磷虾油连续五年在国际权威检测机构ORIVO的抽检中实现零缺陷，并连 续三年获得全球唯一的金标"100%纯油认证"。这一成绩，巩固了NYO3作为全球磷虾油领先品牌的地 位，也让"挪威=纯净磷虾油"的品牌印象深入人心。 如今，NYO3的磷虾油产品已畅销全球20多个国家和地区，覆盖西班牙、意大利、美国、德国、英国等 欧美主流 ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 4.9% for the first half of 2025, with an adjusted EBITDA margin maintained at 15.7% [48][49][64] - Adjusted net profit increased by 4.6%, reaching a net profit margin of 5.2% [49][64] - The gross profit margin improved by 1.4 percentage points for core product categories [55] Business Line Data and Key Metrics Changes - The ANC business grew by 5.9%, BNC by 2.9%, and P&C by 8.6% [22] - Nutritional supplements accounted for 65.6% of total revenue, up by 4.1% [18] - The P&C segment saw a 15.5% growth, while the probiotic business experienced a decline of around 10% [9][19] Market Data and Key Metrics Changes - China contributed 70% of total revenue, with a growth driven by IMF sales and nutritional products [20] - The North American market grew by 4.6%, while the ANZ market saw a decline of 15.6% due to Daigou channel sales [20][21] - Expansion markets contributed 66% of revenue, growing by 18.6% [21] Company Strategy and Development Direction - The company aims to maintain its number one position in the ANC market in China and expand into new markets [44][45] - Focus on premiumization and diversification strategies to enhance profitability and market share [46] - Continued investment in product innovation and consumer education to drive growth [15][44] Management Comments on Operating Environment and Future Outlook - Management acknowledged fierce competition in the Chinese market and emphasized the importance of adapting strategies [3] - The company expects to achieve high single-digit sales growth for the full year, with a stable EBITDA margin around 15% [66] - Confidence in overcoming challenges from the Guo Biao transition and maintaining growth momentum [8][49] Other Important Information - The interim dividend payout is set at HKD0.19 per share [12] - The company completed a refinancing of USD 300 million, which is expected to lower financial expenses [11][51] Q&A Session Summary Question: Do you have any guidance update for the whole year's performance? - The company expects high single-digit growth for the whole group, with adjusted EBITDA margin around 15% and adjusted net profit margin close to 5% [66] Question: What are the key drivers for the B&C business growth? - Main drivers include innovative products and penetration into new channels, with a focus on retail and online channels [70][71] Question: Will the IMF gross profit margin be restructured? - Adjustments are being made to improve profitability, with 80% of product categories returning to expected growth [72][73] Question: What is the expectation for the ANC business in ANZ? - The company will continue to promote domestic business growth to offset declines in the Daigou channel, maintaining guidance for the whole year [85][86]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 4.9% for the first half of 2025, with an adjusted EBITDA margin maintained at 15.7% [48][49][64] - Adjusted net profit increased by 4.6%, reaching a net profit margin of 5.2% [49][64] - The gross profit margin improved by 1.4 percentage points for core product categories [55] Business Line Data and Key Metrics Changes - The ANC business grew by 5.9%, BNC by 2.9%, and P&C by 8.6% [22] - Nutritional supplements accounted for 65.6% of total revenue, showing a 4.1% increase [18] - The P&C business globally saw a 14% growth, with SOLIGO returning to 17.5% growth [10][36] Market Data and Key Metrics Changes - China contributed 70% of total revenue, with a 13% growth in the ANC business [20][5] - The ANZ market experienced a 5.6% growth, while the North American market saw a 4.6% growth [7][38] - Expansion markets contributed 66% of revenue, growing by 18.6% [21] Company Strategy and Development Direction - The company aims to diversify its market and brands while consolidating its core market [24] - Focus on premiumization and innovation in product offerings to drive growth [44][45] - Continued investment in new markets and channels to enhance profitability [46] Management's Comments on Operating Environment and Future Outlook - Management acknowledged fierce competition in the Chinese market and emphasized the importance of strategic adjustments [3] - The company remains confident in achieving high single-digit sales growth for the full year [66] - Future strategies include focusing on super premium segments and expanding into new markets [45][46] Other Important Information - The interim dividend payout is set at HKD0.19 per share [12] - The company completed a refinancing of USD 300 million, which is expected to lower financial expenses [11][51] Q&A Session Summary Question: Do you have any guidance update for the whole year's performance? - The company expects high single-digit growth for the whole group, with adjusted EBITDA margin around 15% and adjusted net profit margin close to 5% [66] Question: What are the key drivers for the B&C business growth? - The main drivers include innovative products and penetration into new channels [70][71] Question: Will the product mix and brand be restructured strategically? - Yes, adjustments are being made to improve profitability, particularly in the non-core IMF and probiotic segments [71][73] Question: What is the expectation for the ANC business in ANZ? - The company will continue to promote growth in domestic channels to offset declines in the Daigou channel [85][87]

Core Insights - Winvest Group Limited's subsidiary IQI Media Inc. has partnered with BioCalth International Inc. to enhance BioCalth's direct-to-consumer sales [1][2] - The partnership includes a content management agreement with profit-sharing incentives aimed at increasing revenue and brand recognition for BioCalth [2][3] - BioCalth has over 25 years of experience in the supplement industry, manufacturing patented products in the USA and exporting globally [3][4] Company Overview - BioCalth is launching its first ecommerce store to introduce its flagship product, calcium L-threonate, which has a 95% absorption rate verified by laboratory research at UCLA [4][5] - The ecommerce site for BioCalth can be accessed at https://biocalth.us/ [6] - Winvest Group Limited is focused on media, entertainment, and technology, with plans to upgrade to Nasdaq and pursue an IPO [7] Strategic Initiatives - IQI Media will implement a top-of-funnel (TOFU) strategy for social marketing to build awareness and trust for BioCalth's products [4][5] - BioCalth is expanding its manufacturing capabilities at its California plant, which is FDA-registered and GMP-certified, to provide services to other companies [4][5] - The integration of sales, data analytics, and backend management is part of BioCalth's core strategy for future growth [5]

Core Insights - USANA announced innovative new products, significant ingredient reformulations, and refreshed packaging at its 2025 Global Convention [1][3] - The introduction of the Health Professional Advisory Council aims to enhance product credibility and customer experience [5][6] Product Developments - New products include Circulate+, Core Aminos, Marine Collagen Peptides, and various Celavive skincare items [8] - Reformulated products consist of BiOmega, CellSentials, HealthPak, and several Celavive products [8] - Rebranded products include Celavive Creamy Foam Cleanser, Conditioning Makeup Remover, and Protective Day Cream/Lotion SPF 30 [8] Strategic Initiatives - The Health Professional Advisory Council will consist of industry experts to support product development and enhance customer experiences [5][6] - The company emphasizes its commitment to providing high-quality nutritional and lifestyle products, backed by over 30 years of trust [7]

Market Overview - The market faced challenges as technology and semiconductor stocks experienced significant selling, raising concerns about high valuations and the sustainability of the AI-driven rally [1] - The S&P 500 and Nasdaq Composite indices declined by 0.24% and 0.67%, respectively, indicating a cautious market sentiment [1] - There is a shift in focus towards value stocks due to the current market conditions [1] Value Stocks Evaluation - The Price to Cash Flow (P/CF) ratio is highlighted as an effective metric for evaluating value stocks, with companies like StoneCo Ltd. (STNE), CVS Health Corporation (CVS), Integer Holdings Corporation (ITGR), and USANA Health Sciences, Inc. (USNA) showing low P/CF ratios [2][10] - A low P/CF ratio indicates a favorable market price relative to the cash flow generated per share, making it a reliable indicator of financial health [5][10] Financial Health Indicators - Positive cash flow is essential for a company's liquidity, enabling it to manage debts, reinvest, and return value to shareholders, while negative cash flow indicates declining liquidity [7] - Analysts emphasize that cash flow is a more reliable measure than earnings, which can be influenced by accounting estimates and management practices [6] Value Investing Strategy - A comprehensive approach to value investing should include multiple metrics such as price-to-book ratio, price-to-earnings ratio, and price-to-sales ratio, alongside the P/CF ratio [8] - Stocks should be selected based on parameters like P/CF less than or equal to the industry median, a minimum price of $5, and a Zacks Rank of 1 or 2 for better performance potential [9][11][13] Company Performance Highlights - StoneCo has a Zacks Rank of 1, with a trailing four-quarter earnings surprise of 11.5%, and is projected to see sales and EPS growth of 7.6% and 10.4%, respectively [13][14] - CVS Health holds a Zacks Rank of 2, with a trailing earnings surprise of 22.6%, and is expected to grow sales and EPS by 4.7% and 16.6%, respectively [15] - Integer Holdings, also with a Zacks Rank of 2, anticipates sales and EPS growth of 7.8% and 20.4%, despite a 13.2% decline in share price over the past year [16] - USANA Health Sciences has a Zacks Rank of 2, with a trailing earnings surprise of 21.6%, and is projected to grow sales and EPS by 11.7% and 1.2%, respectively, despite a 21.1% decline in share price [17]

Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletesLAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc. (OTCMKTS: BDPT), a leader in natural health and performance supplements, today announced that its flagship nootropic formula, MyndMed™, has been officially certified clean by TruShield™ Laboratory Services, a trusted provider of sports supplement testing specializing in World Anti-Doping Agen ...

LAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc. (OTCMKTS: BDPT), a leader in natural health and performance supplements, today announced that its flagship nootropic formula, MyndMed™, has been officially certified clean by TruShield™ Laboratory Services, a trusted provider of sports supplement testing specializing in World Anti-Doping Agency (WADA) compliance. TruShield™ is widely recognized in the athletic community for its rigorous, accredited testing protocols, trusted by profes ...

Core Insights - Abbott Laboratories' Nutrition business is experiencing strong growth and market share gains, driven by high demand for adult nutritional products that combine high protein and low sugar [1][7] - The global nutritional supplements market is projected to reach $704.28 billion by 2030, growing at a CAGR of 6.42% from 2025 to 2030, influenced by increased health consciousness post-COVID-19 and rising non-communicable diseases [2] - Abbott's brands, Ensure and Glucerna, are leading in the market for complete nutrition, while the Similac brand remains the top choice for pediatric nutrition in the U.S. [3][7] Company Performance - Abbott's adult Nutrition segment achieved 6.6% organic growth in Q2 2025, contributing to mid-single-digit organic growth overall [3][7] - Year-to-date, Abbott shares have increased by 16.5%, outperforming the industry growth of 5.9% and the S&P 500's 9.6% [6] Competitive Landscape - Nestlé's Nutrition business offers a wide range of products for all life stages, including infant formulas and adult nutritional drinks [4] - Danone specializes in Early Life Nutrition and Medical Nutrition, providing a variety of infant and child nutrition products as well as condition-specific solutions [5] Valuation Metrics - Abbott currently trades at a forward Price-to-Sales (P/S) ratio of 4.89X, below the industry average of 5.56X [8]